

**CHARACTERIZATION OF AN INDUCIBLE TRANSGENIC  
MOUSE MODEL FOR FRAGILE X-ASSOCIATED  
TREMOR/ATAXIA SYNDROME (FXTAS)**



**THESIS**

**A thesis submitted for the degree of Master of Biomedical Science majoring  
on Genetic Counseling**

**by  
FATWA ADIKUSUMA  
G4A008039**

**POST GRADUATE PROGRAM  
DIPONEGORO UNIVERSITY  
SEMARANG  
2011**

**CHARACTERIZATION OF AN INDUCIBLE TRANSGENIC  
MOUSE MODEL FOR FRAGILE X-ASSOCIATED  
TREMOR/ATAXIA SYNDROME (FXTAS)**



**THESIS**

**A thesis submitted for the degree of Master of Biomedical Science majoring  
on Genetic Counseling**

by  
**FATWA ADIKUSUMA**  
**G4A008039**

**POST GRADUATE PROGRAM  
DIPONEGORO UNIVERSITY  
SEMARANG  
2011**

**THESIS**

**CHARACTERIZATION OF AN INDUCIBLE TRANSGENIC  
MOUSE MODEL FOR FRAGILE X-ASSOCIATED  
TREMOR/ATAXIA SYNDROME (FXTAS)**

By  
FATWA ADIKUSUMA  
G4A008039


Has been defended in front of the defense committee  
On April 13<sup>th</sup>, 2011  
and has been approved by:

**The Netherland**  
Principal Supervisor,



Renate Hukema, PhD

Supervisor,



Rob Willemsen, PhD

**Indonesia**  
Principal Supervisor,

Prof. Sultana MH Faradz, PhD  
NIP. 130 701 415

Supervisor,

Prof. DR. dr. Sarjadi, Sp.PA (K)  
NIP. 130 352 547

Recognition,  
Head of Master's Degree Program in Biomedical Science  
Post Graduate Program Diponegoro University

DR. dr. Winarto Sp.MK, SpM(K)  
NIP. 130 675 157

## **DECLARATION**

I hereby declare that this submission is my own work and that, to the best of my knowledge and belief, it contains no material previously published or written by another person nor material which to a substantial extent has been accepted for the award of any other degree or diploma of the university or other institute of higher learning, except where due acknowledgement is made in the text.

Semarang, April 2011

Fatwa Adikusuma

## ACKNOWLEDGMENT

Thanks God for Your destiny to give me an amazing study experience in this program, Genetic Counseling Biomedical Science Diponegoro University. In this program many people and parties have contributed a lot for my study. I would like to thank to them.

I would like to express my gratitude to my supervisors: Renate Hukema, PhD, Rob Willemsen, PhD, Professor Sultana MH Faradz MD, PhD, and Professor Dr. dr. Sarjadi, SpPA (K) for the supervision, advices and support.

My special thanks to Professor dr. Sultana M.H. Faradz, PhD. Head of Master Biomedical Science Majoring on Genetic Counseling Diponegoro University Semarang for making this study happen and possible. Every single step of this study has your contribution. Thank you for opening this program, encouraging us to have better knowledge and experience, for your care to us, for finding the scholarship, for supervising me, for everything that I couldn't state entirely. Also I won't forget my gratitude for dr. Tri Indah Winarni, MSi.Med for her support to this program as well.

I also thank to Dr. Abe Susanto, MSc from from Bureau of Planning and International Cooperation, Ministry of National Education The republic Indonesia, who has provided the financial support by the program "Beasiswa Unggulan".

I would like to thanks to Professor dr. Ben Oostra PhD and Rob Willemsen PhD, from Department of Clinical Genetics, Erasmus MC Rotterdam, The Netherlands, for making it possible to study and experience an advanced research at their laboratory.

I would like to thank to colleagues in Fragile X group Erasmus MC who gave many contributions whilst I was in the laboratory. Thanks to Edwin Mientjes PhD, Liesanne and Ronald Buijsen.

I would like to extend my acknowledgement to dr. Endang Ambarwati, Sp.RM, dean of the Faculty of Medicine Diponegoro University Semarang, and also to Dr. dr. Winarto, SpMK, SpM (K) Head of Master's Degree Program in Biomedical Science Post Graduate Program Diponegoro University Semarang, Faculty of Medicine, Diponegoro University Semarang.

Last but not least, I would like to thank to my family and many people who contribute in supporting me to finish this study.

Semarang, April 2011

***Fatwa Adikusuma***

## LIST OF ABBREVIATIONS

ASO	: antisense oligonucleotides
(CGG) <sub>n</sub>	: CGG with (n) number of repeat
C57BL/6	: a type of mouse strain which is widely used for laboratory mouse
COS-7	: CV-1 (simian) in Origin, and carrying the SV40 genetic material line 7
DM	: myotonic dystrophy
DMPK	: myotonic dystrophy protein kinase
dox	: doxycycline
eGFP	: enhanced green fluorescent protein
FISH	: fluorescence in situ hybridization
<i>Fmr1</i>	: fragile x mental retardation 1 (for animal)
<i>FMRI</i>	: fragile x mental retardation 1 (for human)
Fmrp	: fragile x mental retardation protein (for animal)
FMRP	: fragile x mental retardation protein (for human)
FXTAS	: fragile x-associated tremor/ataxia syndrome
Gapdh	: glyceraldehyde 3-phosphate dehydrogenase
GFA	: glial fibrillary acidic
GFP	: green fluorescent protein
GLAST	: glutamate–aspartate transporters
hnRNP	: Heterogeneous nuclear ribonucleoproteins

Hsp	: heat shock protein
IP	: intraperitoneal
KI	: knock-in
MBNL1	: muscleblind-like 1
MCP	: middle cerebellar peduncle
MRI	: magnetic resonance imaging
Pcp	: Purkinje cell protein
POF	: premature ovarian failure
PrP	: prion protein
RT-Q-PCR	: reverse transcriptase-quantitative-polymerase chain reaction
rtTA	: reverse-tetracycline transactivator
SCA	: spinocerebellar ataxia
Tet	: tetracycline
UTR	: untranslated region
ZNF9	: zinc finger protein 9



## TABLE OF CONTENTS

DECLARATION .....	iv
ACKNOWLEDGMENT.....	v
LIST OF ABBREVIATIONS .....	vii
TABLE OF CONTENTS.....	ix
LIST OF TABLE, FIGURES, AND APPENDICES.....	xi
ABSTRACT.....	xiii
ABSTRAK.....	xiv
CHAPTER 1	
INTRODUCTION .....	1
1.1. BACKGROUND .....	1
1.2. RESEARCH QUESTIONS.....	5
1.3. RESEARCH PURPOSES.....	6
1.4. RESEARCH BENEFITS .....	7
1.5. RESEARCH ORIGINALITY .....	7
CHAPTER 2	
LITERATURE REVIEW .....	8
2.1. FXTAS: THE <i>FMRI</i> GENE AND CLINICAL ASPECTS.....	8
2.2. NEUROPATHOLOGICAL OF FXTAS .....	11
2.3. MOLECULAR PATHOGENESIS OF FXTAS .....	14
2.4. MOUSE MODEL OF FXTAS.....	17
CHAPTER 3	
THEORITICAL FRAMEWORK, CONCEPTUAL FRAMEWORK, AND HYPOTHESES .....	20
3.1. THEORITICAL FRAMEWORK .....	20
3.2. CONCEPTUAL FRAMEWORK.....	21
3.3. HYPOTHESES .....	22
CHAPTER 4	
RESEARCH METHODS .....	23
4.1. RESEARCH FIELD .....	23
4.2. SETTING/LOCATION, RESEARCH PERIOD .....	23

4.3. RESEARCH DESIGN .....	23
4.4. POPULATIONS AND SAMPLES.....	23
4.5. RESEARCH VARIABLES .....	24
4.6. OPERATIONAL DEFINITIONS.....	25
4.7. RESEARCH PROTOCOLS .....	27
4.8. FRAMEWORK OF RESEARCH.....	36
4.9. DATA ANALYSIS.....	44
4.10. ETHICAL IMPLICATION.....	44
CHAPTER 5	
RESULTS .....	45
5.1. Previous study: cell culture and organotypical slices .....	45
5.2. The workable of Tet-on-nCGG-eGFP: <i>in vivo</i> study using Tet-on-nCGG-eGFP/hnRNP-rtTA .....	45
5.3. The workable of Tet-on-99CGG-eGFP/GFA2-rtTA <i>in vivo</i> .....	48
5.4. The workable of Tet-on-99CGG-eGFP/PrP-rtTA <i>in vivo</i> .....	48
5.5. Transgene expression outside the brain in Tet-on-99CGG-eGFP/PrP-rtTA bigenic mice.....	50
5.6. Best founder of PrP-rtTA.....	53
5.7. Best founder of Tet-on-99CGG-eGFP .....	54
5.8. Formation of ubiquitin intranuclear inclusion in the Tet-on-99CGG-eGFP/PrP-rtTA bigenic mice .....	57
CHAPTER 6	
DISCUSSION.....	62
6.1. Leakage of Tet-on-99CGG-eGFP/PrP-rtTA.....	63
6.2. Toxic RNA and inclusions.....	64
6.3. Reversibility study .....	66
6.4. Astrocytes and glutamate excitotoxicity involvement for disease progression .....	67
CHAPTER 7	
CONCLUSION AND SUGGESTION.....	72
REFERENCES .....	73
CURRICULUM VITAE.....	81
APPENDICES .....	85

## LIST OF TABLE, FIGURES, AND APPENDICES

### Tables

Table 1. Proteins found in the human brain inclusions

### Figures

Figure 1. CGG length, *FMRI* expression and the clinical outcomes

Figure 2. Ubiquitin-positive intranuclear inclusions in human neurons, human astrocytes, murine neurons

Figure 3. Immunohistochemistry for GFP in liver, kidney, and intestine of bigenic mice Tet-on-nCGG-eGFP/hnRNP-rtTA with dox treatment

Figure 4. Immunohistochemistry for GFP in brain slices of bigenic mice Tet-on-99CGG-eGFP/PrP-rtTA after 2 weeks of dox in drinking treatment

Figure 5. Immunohistochemistry for GFP in tissues outside the brain of bigenic mice Tet-on-99CGG-eGFP/PrP-rtTA after dox intraperitoneal injection

Figure 6. Western blot for GFP on kidney of tet-on-99CGG-eGFP/PrP-rtTA mouse after dox IP treatment

Figure 7. RT-Q-PCR for GFP RNA from kidney of tet-on-99CGG-eGFP/PrP-rtTA mouse after dox IP treatment

Figure 8. rtTA mRNA levels from the brains of different PrP-rtTA founder

Figure 9. Immunohistochemistry for GFP in the liver slices comparing founder 31 and 39 of Tet-on-99CGG-eGFP

Figure 10. GFP RNA levels in the liver comparing founder 31 and 39 of Tet-on-99CGG-eGFP

Figure 11. Western blot analysis for GFP in the liver comparing founder 31 and 39 of Tet-on-99CGG-eGFP

Figure 12. Immunohistochemistry for GFP in the brain slices of bigenic mice Tet-on-99CGG-eGFP/PrP-rtTA after dox treatment

Figure 13. GFP RNA levels in the brain of bigenic mice Tet-on-99CGG-eGFP/PrP-rtTA after dox treatments

Figure 14. Western blot for GFP of bigenic mice Tet-on-99CGG-eGFP/PrP-rtTA after different time points of dox treatment

Figure 15. Immunohistochemistry of ubiquitin in the brain slices of bigenic mice Tet-on-99CGG-eGFP/PrP-rtTA with 12 and 16 weeks of dox treatment

## **Appendices**

Appendix 1. rtTA RT-Q-PCR from brain result for choosing the best PrP-rtTA founder

Appendix 2. Western blot for GFP in liver of mice from founder 39 vs 31 of Tet-on-99CGG-eGFP

Appendix 3. RT-Q-PCR for GFP in liver of mice from founder 39 vs 31 of Tet-on-99CGG-eGFPA

Appendix 4. RT-Q-PCR for GFP after different time points of dox treatment

Appendix 5. Western blot for GFP after different time points of dox treatment

Appendix 6. Ethical clearance document

## ABSTRACT

**Background:** FXTAS (fragile X-associated tremor/ataxia syndrome) is a neurodegenerative disease with tremor and ataxia as the primary symptoms and ubiquitin-positive intranuclear inclusions as the major neuropathological hallmark. FXTAS affects premutation males with an expanded premutation CGG repeat in the promoter of the *FMRI* gene. The expanded premutation CGG RNA is considered toxic. Inducible transgenic mice were generated, using the Tet-on system to express transgene expanded premutation 99CGG along with an eGFP reporter under control of dox (doxycycline) induction, as well as specific driver promoter, the GFA2-rtTA and PrP-rtTA. This study aims to characterize those mouse models so they would be ready to be used for further studies.

**Methods:** Immunohistochemistry, Western blot, and RT-Q-PCR techniques were used to characterize the transgene expression of the transgenic mice. Characterization of ubiquitin inclusions formation used immunohistochemistry technique.

**Results:** The Tet-on-99CGG-eGFP transgene worked *in vivo*, while Tet-on-11CGG-eGFP lost its expression. Tet-on-99CGG-eGFP/GFA2-rtTA bigenic mice did not work *in vivo*, while Tet-on-99CGG-eGFP/PrP-rtTA bigenic mice did work. As expected, the Tet-on-99CGG-eGFP/PrP-rtTA mice formed the FXTAS hallmark, the ubiquitin-positive intranuclear inclusions after 12 weeks of dox induction.

**Conclusions:** Mouse model Tet-on-99CGG-eGFP/PrP-rtTA worked well, and were ready to be used for main further studies.

---

Keywords: FXTAS, *FMRI* gene, transgenic mice, Tet-on, PrP, GFA2, reversibility, ubiquitin inclusions

## ABSTRAK

**Latar belakang:** FXTAS (*fragile X-associated tremor/ataxia syndrome*) merupakan penyakit neurodegeneratif dengan gejala utama tremor dan ataxia serta inklusi intranuklear ubiquitin yang muncul sebagai ciri-ciri utama secara neuropatologikal. FXTAS menyerang pria premutasi yang mengalami ekspansi repetasi CGG di promotor gen *FMRI*. RNA CGG premutasi dipercaya toksik. Tikus transgenik yang dapat diinduksi sudah dibuat, dengan menggunakan sistem Tet-on untuk mengekspresikan transgen 99CGG terekspansi bersama-sama dengan reporter eGFP, serta dapat dikontrol melalui induksi dox (doxycycline), juga menggunakan promotor pengendali yang spesifik yaitu GFA2-rtTA dan PrP-rtTA. Studi ini bertujuan untuk mengkarakterisasi tikus tersebut sehingga model tikus tersebut siap untuk digunakan untuk studi-studi berikutnya.

**Metode:** Teknik imunohistokimia, Western blot, dan RT-Q-PCR digunakan untuk mengkarakterisasi ekspresi transgene pada tikus transgenik. Karakterisasi inklusi ubiquitin menggunakan teknik imunohistokimia.

**Hasil:** Transgen Tet-on-99CGG-eGFP dapat bekerja secara *in vivo*, tetapi Tet-on-11CGG-eGFP kehilangan ekspresi transgennya. Tikus bigenik Tet-on-99CGG-eGFP/GFA2-rtTA tidak bekerja, sedangkan tikus bigenik Tet-on-99CGG-eGFP/PrP-rtTA dapat bekerja dengan baik. Sesuai harapan, tikus bigenik Tet-on-99CGG-eGFP/PrP-rtTA dapat menghasilkan inklusi intranuklear ubiquitin setelah induksi dox selama 12 minggu.

**Kesimpulan:** Model tikus Tet-on-99CGG-eGFP/PrP-rtTA dapat bekerja dengan baik dan siap untuk digunakan untuk studi penting berikutnya

---

Kata kunci: FXTAS, gen *FMRI*, tikus transgenik, Tet-on, PrP, GFA2, reversibilitas, inklusi ubiquitin